Brian Agan, MD

Brian K Agan, MD

Name: Brian K Agan, MD

USU Department of Primary Appointment: 
Preventive Medicine and Biostatistics
Title: 
Deputy Science Director; HIV Research Area Director
Faculty Rank: 
Associate Professor
Location: 
Uniformed Services University of the Health Sciences, Bethesda, MD

Research Interests:
HIV outcomes: pathogenesis, management, and prevention
HIV antiretroviral therapy; HIV associated neurocognitive disorders

Office Phone: 
(301) 816-8446

Education

BA - Chemistry; Colorado College, Colorado Springs, CO
MD - University of Colorado School of Medicine, Denver, CO
Internship & Residency - Internal Medicine; Wilford Hall USAF Medical Center, San Antonio, TX
Fellowship - Infectious Diseases; Wilford Hall USAF Medical Center, San Antonio, TX

Bibliography

  • O'Bryan TA, Agan BK, Tracy RP, Freiberg MS, Okulicz JF, So-Armah K, Ganesan A, Rimland D, Lalani T, Deiss RG, Tramont EC. Racial Comparison of D-dimer Levels in U.S. Male Military Personnel Before and After HIV Infection and Viral Suppression. J Acquir Immune Defic Syndr 2018 Jan 8.
  • Emuren L, Welles S, Evans AA, Polansky M, Okulicz JF, Macalino G, Agan BK; Infectious Disease Clinical Research Program HIV Working Group. Health-related quality of life among military HIV patients on antiretroviral therapy. PLoS One 2017 Jun 7;12(6):e0178953.
  • Crum-Cianflone NF, Won S, Lee R, Lalani T, Ganesan A, Burgess T, Agan BK. Vitamin D levels and influenza vaccine immunogenicity among HIV-infected and HIV-uninfected adults. Vaccine 2016 Sep 22;34(41):5040-6.
  • Freiberg MS, Bebu I, Tracy R, So-Armah K, Okulicz J, Ganesan A, Armstrong A, O'Bryan T, Rimland D, Justice AC, Agan BK; Infectious Disease Clinical Research Program HIV Working Group. D-Dimer Levels before HIV Seroconversion Remain Elevated Even after Viral Suppression and Are Associated with an Increased Risk of Non-AIDS Events. PLoS One. 2016 Apr 18;11(4):e0152588.
  • Bello KJ, Mesner O, O'Bryan TA, Won SH, Lalani T, Ganesan A, Agan BK, Okulicz JF. Factors associated with 10 years of continuous viral load suppression on HAART. BMC Infect Dis 2016 Jul 22;16:351.
  • Okulicz JF, Le TD, Agan BK, Camargo JF, Landrum ML, Wright E, Dolan MJ, Ganesan A, Ferguson TM, Smith DM, Richman DD, Little SJ, Clark RA, He W, Ahuja SK. Influence of the timing of antiretroviral therapy on the potential for normalization of immune status in human immunodeficiency virus 1-infected individuals. JAMA Intern Med 2015 Jan;175(1):88-99.
  • Crum-Cianflone NF, Wang X, Ganesan A, Okulicz J, Weintrob A, Lalani T, Agan B. HIV RNA Levels Predict AIDS-Defining and Non-AIDS-Defining Cancers After Antiretroviral Therapy Initiation Among HIV-Infected Adults. AIDS Res Hum Retroviruses 2015 May;31(5):514-8.
  • Bebu I, Tate J, Rimland D, Mesner O, Macalino GE, Ganesan A, Okulicz JF, Bavaro M, Weintrob AC, Justice AC, Agan BK; the Infectious Disease Clinical Research Program HIV Working Group. The VACS Index Predicts Mortality In A Young, Healthy HIV Population Starting Highly Active Antiretroviral Therapy. J Acquir Immune Defic Syndr 2014 Feb 1;65(2):226-30.
  • Crum-Cianflone NF, Moore DJ, Letendre S, Roediger M, Eberly L, Weintrob A, Ganesan A, Johnson E, Del Rosario R, Agan BK, Hale BR. Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons. Neurology 80(4): 371-379, 2013 Jan 23.
  • Burt TD*, Agan BK*, Marconi VC, He W, Kulkarni H, Mold JE, Cavrois M, Huang Y, Mahley RW, Dolan MJ, McCune JM, Ahuja SK. Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE epsilon4/epsilon4 genotype accelerates HIV disease progression. Proceedings of the National Academy of Sciences of the United States of America 105(25):8718-23, 2008 Jun 24.